Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (515)	5/15/2003 12:22:02 PM
From: tuck	Read Replies (1) \| Respond to of 897

Got to give IDBE credit for their timing, but near to intermediate term, this helps BSCP: >>TORONTO, May 15 (Reuters) - ID Biomedical Corp. (Toronto:IDB.TO - News) said on Thursday it will offer $22 million in shares to raise funds for development of its nasal influenza vaccine and other general corporate purposes. The company said a syndicate of underwriters, in connection with its previously announced offering of 2.6 million shares, would offer the shares for $8.50 each. The offering is expected to close around May 28. Shares of ID Biomedical, which were halted pending the news, were down C$1.13, or 8.5 percent, at C$12.10 on the Toronto Stock Exchange (News - Websites) on Thursday morning.<< Cheers, Tuck